Atypical antipsychotic drugs and ethanol withdrawal syndrome: A review

Alcohol and Alcoholism

Volumn 47, Issue 1, 2012, Pages 33-41

  Uzbay, Tayfun I ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALCOHOL; ALPHA 2 ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE; OLANZAPINE; OPIATE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; ZIPRASIDONE;

ADDICTION; AGITATION; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; AUDIOGENIC SEIZURE; BODY POSTURE; CLINICAL ASSESSMENT; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; GAIT DISORDER; HUMAN; HYPERACTIVITY; LOCOMOTION; MOTOR DYSFUNCTION; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RECEPTOR AFFINITY; RETROSPECTIVE STUDY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT RESPONSE; TREMOR;

ALCOHOLISM; ANIMALS; ANTIPSYCHOTIC AGENTS; ETHANOL; HUMANS; RATS; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALIA; CANIS FAMILIARIS; RATTUS; RATTUS NORVEGICUS;

EID: 84555178687     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agr142     Document Type: Review

References (95)

1. Alldregge BK. (1999) Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 53:S68-75.
2. Ashby CR, Jr, Wang RY. (1996) Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24:349-94.
3. Batel P. (2000) Addiction and schizophrenia. Eur Psychiatry 15:115-22.
4. Bowers MB, Jr, Mazure CM, Nelson JC et al. (1990) Psychotogenic drug use and neuroleptic response. Schizophr Bull 16:81-5.
5. Brust JCM. (2004) Neurological Aspects of Substance Abuse, 2nd edn. Philadelphia: Elsevier Butterworth-Heinemann, 334.
6. Carlsson C, Gullberg B. (1978) A double blind study with melperone and placebo in the treatment of chronic alcoholics. Int J Clin Pharmacol Biopharm 16:331-2.
7. Celikyurt IK, Kayir H, Ulak G et al. (2011) Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats. Prog Neuropsychopharmacol Biol Psychiatry 35:528-36.
8. Ciccocioppo R. (1999) The role of serotonin in craving: from basic research to human studies. Alcohol 34:244-53.
9. Conroy SK, Rodd Z, Chambers RA. (2007) Ethanol sensitization in a neurodevelopmental lesion model of schizophrenia in rats. Pharmacol Biochem Behav 86:386-94.
10. Dall'Olio R, Gandolfi O, Vaccheri A et al. (1988) Changes in behavioural responses to the combined administration of D1 and D2 dopamine agonists in normosensitive and D1 supersensitive rats. Psychopharmacology 95:381-5.
11. Di Chiara G. (1995) The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 38:95-137.
12. Drake RE, Xie H, McHugo GJ et al. (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26:441-9.
13. D'Souza DC, Gil RB, Madonick S et al. (2006) Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia. Neuropsychopharmacology 31:2767-75.
14. Erdoan S. (2010) Quetiapine in substance use disorders, abuse and dependence possibility: a review. Turk Psikiyatri Derg 21:167-75.
15. Feldman DJ, Frank RA, Kehne JH et al. (1997) Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior. Pharmacol Biochem Behav 58:565-72.
16. Flanagan RJ, Dunk L. (2008) Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 23(Suppl.1): 27-41.
17. Fone KC, Robinson AJ, Marsden CA. (1991) Characterization of the 5-HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5-HT agonists in rats. Br J Pharmacol 103:1547-55.
18. Gerald MC, Richter NA. (1976) Studies on the effects of histaminergic agents on seizure susceptibility in mice. Psychopharmacologia 46:277-82.
19. Hambrecht M, Hafner H. (1996) Substance abuse and the onset of schizophrenia. Biol Psychiatry 40:1155-63.
20. Hauber W, Lutz S. (1999) Dopamine D1 or D2 receptor blockade in the globus pallidus produces akinesia in the rat. Behav Brain Res 106:143-50.
21. Hauber W, Münkle M. (1997) Motor depressant effects mediated by dopamine D2 and adenosine A2A receptors in the nucleus accumbens and the caudate-putamen. Eur J Pharmacol 323:127-31.
22. Hauber W, Lutz S, Münkle M. (1998) The effects of globus pallidus lesions on dopamine-dependent motor behaviour in rats. Neuroscience 86:147-57.
23. Hedges D, Jeppson K, Whitehead P. (2003) Antipsychotic medication and seizures: a review. Drugs Today 39:551-7.
24. Heimer L, Alheid GF, de Olmos JS et al. (1997) The accumbens: beyond the core-shell dichotomy. J Neuropsychiatry Clin Neurosci 9:354-81.
25. Helzer D, Pryzbeck TR. (1988) The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol 49:219-24.
26. Hochenegg L. (1981) Clopentixol decanoate in the treatment of chronic alcoholism. Acta Psychiatr Belg 81:121-7.
27. Hutchison KE, Swift R, Rohsenow DJ et al. (2001) Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology 155:27-34.
28. Hutchison KE, Wooden A, Swift RM et al. (2003) Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 28:1882-8.
29. Ingman K, Korpi ER. (2006) Alcohol drinking of alcohol-preferring AA rats is differentially affected by clozapine and olanzapine. Eur J Pharmacol 534:133-40.
30. Ingman K, Honkanen A, Hyytiä P et al. (2003) Risperidone reduces limited access alcohol drinking in alcohol-preferring rats. Eur J Pharmacol 468:121-7.
31. Jaffe JH. (1990) Drug addiction and drug abuse. In Gilman AG, Rall TW, Wies AS (eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: Pergamon Press, 522-73.
32. Kayir H, Uzbay T. (2008) Effects of clozapine on ethanol withdrawal syndrome in rats. Alcohol Alcohol 43:619-25.
33. Kenna GA, McGeary JE, Swift RM. (2004) Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. Am J Health Syst Pharm 61:2380-90.
34. Kennedy A, Wood AE, Saxon AJ et al. (2008) Quetiapine for the treatment of cocaine dependence: an open-label trial. J Clin Psychopharmacol 28:221-4.
35. Lal H, Prather PL, Rezazadeh SM. (1993) Potential role of 5-HT1C and/or 5-HT2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. Alcohol Clin Exp Res 17:411-7.
36. LeMarquand D, Pihl RO, Benkelfat C. (1994) Serotonin and alcohol intake, abuse, and dependence: findings of animal studies. Biol Psychiatry 36:395-421.
37. Longoni R, Spina L, Di Chiara G. (1987) Permissive role of D-1 receptor stimulation for the expression of D-2 mediated behavioral responses: a quantitative phenomenological study in rats. Life Sci 41:2135-45.
38. Magnusson O, Fowler CJ, Köhler C et al. (1986) Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology 25:187-97.
39. Majchrowicz E. (1975) Induction of physical dependence upon ethanol and the associated behavioral changes in rats. Psychopharmacologia 43:1993-6.
40. Martinotti G, Andreoli S, Di Nicola M et al. (2008) Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 23:417-24.
41. Meltzer HY. (1995) The role of serotonin in schizophrenia and the place of serotonine-dopamine antagonist antipsychotics. J Clin Psychopharmacol 15(1 Suppl.1):2S-3S.
42. Meltzer HY. (1997) Treatment-resistant schizophrenia: the role of clozapine. Curr Med Res Opin 14:1-20.
43. Mirowsky Y, Wagner GC, Sekowski A et al. (1995) Simultaneous changes in striatal dopamine, serotonin, and their metabolites after withdrawal seizures in rats from dependence on alcohol. Alcohol 12:251-56.
44. Morin AK. (2007) Possible intranasal quetipine misuse. Am J Health Syst Pharm 64:723-5.
45. Murphy JM, McBride WJ, Lumeng L et al. (1987) Contents of monoamines in forebrain regions of alcohol-preferring (P) and -nonpreferring (NP) lines of rats. Pharmacol Biochem Behav 26:389-92.
46. Myers RD, Martin GE. (1973) The role of cerebral serotonin in the ethanol preference of animals. Ann NY Acad Sci 215:135-44.
47. Nasrallah HA. (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding properties. Mol Psychiatry 13:27-35.
48. Noble E. (1996) The gene that rewards alcoholism. Sci Am Sci Med 3:52-61.
49. O'Brien CP. (1996) Drug addiction and drug abuse. In Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 557-75.
50. Overall JE. (1973) Drug treatment of anxiety and depression in detoxified alcoholic patients. Arch Gen Psychiatry 29:218-25.
51. Overstreet DH, Knapp DJ, Moy SS et al. (2003) A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacolgoy 167:344-52.
52. Overstreet DH, Knapp DJ, Angel RA et al. (2006) Reduction in repeated ethanol- withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands. Psychopharmacology 187:1-12.
53. Paparrigopoulos T, Karaiskos D, Liappas J. (2008) Quetiapine: another drug with potential for misuse? A case report. J Clin Psychiatry 69:162-3.
54. Pinkofsky HB, Hahn AM, Campbell FA et al. (2005) Reduction of opioid-withdrawal symptoms with quetiapine. J Clin Psychiatry 66:1285-8.
55. Potvin S, Stip E, Roy JY. (2003) Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 18:121-32.
56. Reeves RR, Brister JC. (2007) Additional evidence of the abuse potential of quetiapine. South Med J 100:834-6.
57. Regier D, Farmer M, Rae D et al. (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. J Am Med Assoc 264:2511-8.
58. Richtand NM, Welge JA, Logue AD et al. (2007) Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropharmacology 32:1715-26.
59. Robinson TE, Berridge KC. (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18:247-91.
60. Roy A, Virkunnen M, Linnolia M. (1987) Reduced central serotonin turnover in subgroup of alcoholics. Biol Psychiatry 11:173-7.
61. Sattar SP, Bhatia SC, Petty F. (2004) Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 29:452-7.
62. Schatzberg AF, Cole JO, DeBattista C. Manuel of Clinical Pharmacology, 4th edn. Washington, DC: American Psychiatric Publishing Inc., 159-244.
63. Schuckit MA. (1996) Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol 64:669-76.
64. Seeman P, Schwarz J, Chen JF et al. (2006) Psychosis pathways converge via D2 high dopamine receptors. Synapse 60: 319-49.
65. Semenova TP, Tiku MK. (1997) Interactions between the serotoninergic and noradrenergic systems of the brain and their role in the regulation of animal behavior. Neurosci Behav Physiol 27:280-2.
66. Sharif ZA. (2003) Pharmacokinetics, metabolism, and drug-drug interaction of atypical antipsychotics in special populations. J Clin Psychiatry 5(Suppl. 6):22-5.
67. Singhal SK, Zhang L, Morales M et al. (2007) Antipsychotic clozapine inhibits the function of a7-nicotinic acetylcholine receptors. Neuropharmacology 52:387-94.
68. Siris SG. (1990) Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 16:111-22.
69. Smelson DA, Losonczy MF, Davis CW et al. (2002) Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 47:671-5.
70. Smelson DA, Williams J, Ziedonis D et al. (2004) A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat 27:45-9.
71. Stefan M, Travis M, Murray RM. (2002) An Atlas of Schizophrenia. London: The Parthenon Publishing Group.
72. Sturman G, Freeman P, Quinn L. (2001) Histamine H1-antagonists potentiate seizures in the EL (epilepsy-like) mouse model of temporal lobe epilepsy. Inflamm Res 50(Suppl. 2):S80-1.
73. Stuyt EB, Sajbel TA, Allen MH. (2006) Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict 15:166-73.
74. Svensson TH. (2003) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1145-58.
75. Takao K, Nagatani T, Kitamura Y et al. (1995) Chronic forced swim stress of rats increases frontal cortical 5-HT2 receptors and the wet-dog shakes they mediate, but not frontal cortical beta-adrenoceptors. Eur J Pharmacol 294:721-6.
76. Thompson WL. (1978) Management of alcohol withdrawal syndromes. Arch Int Med 138:278-83.
77. Thrasher MJ, Freeman PA, Risinger FO. (1999) Clozapine's effects on ethanol's motivational properties. Alcohol Clin Exp Res 23:1377-85.
78. Trzaskowska E, Krzascik P, Staniszewska A et al. (1989) On the relative importance of D-1 vs. D-2 dopaminergic receptors in the control of audiogenic seizures in ethanol withdrawn rats. Drug Alcohol Depend 24:265-7.
79. Unsalan N, Saglam E, Kayir H et al. (2008) Effects of olanzapine on ethanol withdrawal syndrome in rats. Eur J Pharmacol 579:208-14.
80. Uzbay IT. (2008) Serotonergic anti-depressants and ethanol withdrawal syndrome: a review. Alcohol Alcohol 43:15-24.
81. Uzbay IT. (2009) New pharmacological approaches to the treatment of schizophrenia. Turk Psikiyatri Derg 20:175-82.
82. Uzbay IT, Kayaalp SO. (1995) A modified liquid diet of chronic ethanol administration: validation by ethanol withdrawal syndrome in rats. Pharmacol Res 31:37-42.
83. Uzbay IT, Akarsu ES, Kayaalp SO. (1994) Effects of bromocriptine and haloperidol on ethanol withdrawal syndrome in rats. Pharmacol Biochem Behav 49:969-74.
84. Uzbay IT, Erden BF, Tapanyigit EE et al. (1997) Nitric oxide synthase inhibition attenuates signs of ethanol withdrawal in rats. Life Sci 61:2197-209.
85. Uzbay IT, Usanmaz S, Tapanyiit EE et al. (1998) Dopaminergic and serotonergic alterations in the rat brain during ethanol withdrawal: association with behavioral signs. Drug Alcohol Depend 53:39-47.
86. Uzbay IT, Usanmaz SE, Akarsu ES. (2000) Effects of chronic ethanol administration on serotonin metabolism in the various regions of the rat brain. Neurochem Res 25:257-62.
87. Uzbay IT, Saglam E, Kayir H et al. (2004) Effects of fluoxetine on ethanol withdrawal syndrome in rats. J Psychiatr Res 38:445-50.
88. Vergne DE, Anton RF. (2010) Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS Neurol Disord Drug Targets 9:50-4.
89. Volkow ND, Fowler JS, Wang GJ et al. (2004) Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9:557-69.
90. Walker BM, Rasmussen DD, Raskind MA et al. (2008) Alpha1-noradrenergic receptor antagonism blocks dependenceinduced increases in responding for ethanol. Alcohol 42:91-7.
91. Walter H, Ramskogler K, Semler B et al. (2001) Dopamine and alcohol relapse: D1 and D2 antagonists increase relapse rates in animal studies and in clinical trials. J Biomed Sci 8:83-8.
92. Wines JD, Jr, Weiss RD. (1999) Opioid withdrawal during risperidone treatment. J Clin Psychopharmacol 19:265-7.
93. Yap CY, Taylor DA. (1983) Involvement of 5-HT2 receptors in the wet-dog shake behaviour induced by 5-hydroxytryptophan in the rat. Neuropharmacology 22:801-4.
94. Young CR, Bowers MB, Mazure CM. (1998) Management of the adverse effects of clozapine. Schizophr Bull 24:381-90.
95. Yu L, Fisher H, Wagner GC. (2000) Monoaminergic changes associated with audiogenic seizures in ethanol-dependent rats. Prog NeuroPsychopharmacol Biol Psychiatry 24:1379-92.